Efficacy of Remote Neuromodulation for Migraine Prevention: Stewart J. Tepper, MD
At the 2023 AAN Annual Meeting, the professor of neurology at the Geisel School of Medicine at Dartmouth talked about the effectiveness of a remote electrical neuromodulation device that offers potential relief for both episodic and chronic migraine. [WATCH TIME: 3 minutes]
WATCH TIME: 3 minutes
“The remote electrical neuromodulation device was administered for 45 minutes every other day for 2 months, and the end point was gathered in the second month. Most preventive studies do at least 3months. This showed statistically significant differences from placebo so quickly such that we anticipate that this will be extremely useful for patients in the future.”
Over 1 billion patients worldwide are affected by migraines, causing significant disability to patients and increased socioeconomic burden.1 In the migraine community, preventive treatments are underutilized even though they are part of the key to managing the condition. Thus, there is an unmet need for nonpharmacological interventions for migraine prevention that are both well-tolerated and effective. One intervention for migraine is remote electrical neuromodulation (REN), which is being evaluated in clinical trials for both episodic and chronic migraine.
Recent data from the double-blind randomized sham-controlled clinical trial (NCT04828707) of Nerivio, Theranica’s REN device demonstrated superiority in efficacy and safety compared with placebo as a treatment for migraine prevention in both of these groups.1 Lead author Stewart J. Tepper, MD, presented the study’s findings as an abstract presentation in the advances in migraine therapeutics session at the 2023 American Academy of Neurology (AAN) Annual Meeting, April 22-27, in Boston, Massachusetts.
Tepper, professor of neurology at the Geisel School of Medicine at Dartmouth and director of the Dartmouth Headache Center at Dartmouth Health, sat down with NeurologyLive® in an interview at the meeting to discuss the key findings from the study and how the REN device works to prevent migraine. He also explained the duration and frequency of usage for the device, and how it quickly demonstrated statistically significant differences in migraine reduction compared with placebo. In addition, Tepper spoke about the implications the research has for the future treatment of migraines.
Click here for more coverage on AAN 2023.
